Insights

High Investor Interest Dyne Therapeutics has attracted significant investor interest recently, with Renfund and Commodore Capital making multi-million dollar investments into the company. This shows a potential opportunity for sales by leveraging the company's growing financial backing.

Recent Clinical Trial Data The launch of clinical data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD has demonstrated compelling results. This positive outcome provides a sales opportunity to showcase the efficacy of Dyne Therapeutics' products to potential partners or customers.

Leadership Changes Dyne Therapeutics has experienced changes in leadership, with the appointment of John Cox as CEO and departure of Joshua Brumm. Leveraging the arrival of a new CEO could open doors for sales initiatives targeting partnerships or collaborations under fresh leadership.

Technology Stack Utilization With a tech stack including Akamai, Jupyter, and Microsoft, Dyne Therapeutics demonstrates a commitment to leveraging advanced technologies. Highlighting the company's technological capabilities in sales pitches could attract tech-savvy clients seeking innovative solutions.

Broad Pipeline and Funding Dyne Therapeutics has a broad pipeline for serious muscle diseases and a substantial funding of $326 million. This provides a sales opportunity to engage with potential collaborators or investors interested in partnering with a well-funded company with a diverse therapeutic portfolio.

Similar companies to Dyne Therapeutics

Dyne Therapeutics Tech Stack

Dyne Therapeutics uses 8 technology products and services including Akamai, Jupyter, Popper, and more. Explore Dyne Therapeutics's tech stack below.

Akamai
Content Delivery Network
Jupyter
File Sharing
Popper
Miscellaneous
Microsoft
Miscellaneous
Module Federation
Miscellaneous
Yoast SEO
Search Engines
HSTS
Security
Acquia Cloud Site Factory
Web Hosting

Media & News

Dyne Therapeutics's Email Address Formats

Dyne Therapeutics uses at least 1 format(s):

Dyne Therapeutics Email Formats	Example	Percentage
FLast@dyne-tx.com	JDoe@dyne-tx.com	93%
First.Last@dyne-tx.com	John.Doe@dyne-tx.com	6%
Last@dyne-tx.com	Doe@dyne-tx.com	1%

Frequently Asked Questions

Where is Dyne Therapeutics's headquarters located?

Dyne Therapeutics's main headquarters is located at 1560 Trapelo Rd Waltham, Massachusetts 02451 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Dyne Therapeutics's phone number?

You can contact Dyne Therapeutics's main corporate office by phone at

+1-857-201-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Dyne Therapeutics's stock symbol?

Dyne Therapeutics is a publicly traded company; the company's stock symbol is DYN.

What is Dyne Therapeutics's official website and social media links?

Dyne Therapeutics's official website is dyne-tx.com and has social profiles on LinkedIn.

How much revenue does Dyne Therapeutics generate?

As of September 2024, Dyne Therapeutics's annual revenue reached $35M.

What is Dyne Therapeutics's SIC code NAICS code?

Dyne Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Dyne Therapeutics have currently?

As of September 2024, Dyne Therapeutics has approximately 177 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: J. C.Chief Medical Affairs Officer: A. D.Chief Scientific Officer: O. B.. Explore Dyne Therapeutics's employee directory with LeadIQ.

What industry does Dyne Therapeutics belong to?

Dyne Therapeutics operates in the Biotechnology Research industry.

What technology does Dyne Therapeutics use?

Dyne Therapeutics's tech stack includes AkamaiJupyterPopperMicrosoftModule FederationYoast SEOHSTSAcquia Cloud Site Factory.

What is Dyne Therapeutics's email format?

Dyne Therapeutics's email format typically follows the pattern of . Find more Dyne Therapeutics email formats with LeadIQ.

How much funding has Dyne Therapeutics raised to date?

As of September 2024, Dyne Therapeutics has raised $326M in funding. The last funding round occurred on May 21, 2024 for $326M.

When was Dyne Therapeutics founded?

Dyne Therapeutics was founded in 2018.

Dyne Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com. 

To view our community guidelines, click here: https://bit.ly/3BYPnpK

Company Overview

Headquarters: 1560 Trapelo Rd Waltham, Massachusetts 02451 US
Phone number: ✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
+1-857-201-****
Website: dyne-tx.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: DYN
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2018
Employees: 51-200

Media & News

Funding & Financials

$326M
Dyne Therapeutics has raised a total of $326M of funding over 6 rounds. Their latest funding round was raised on May 21, 2024 in the amount of $326M.
$10M$50M
Dyne Therapeutics's revenue is in the range of $10M$50M

Funding & Financials

$326M
Dyne Therapeutics has raised a total of $326M of funding over 6 rounds. Their latest funding round was raised on May 21, 2024 in the amount of $326M.
$10M$50M
Dyne Therapeutics's revenue is in the range of $10M$50M

Company Leadership

J. C.
Chief Executive Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. D.
Chief Medical Affairs Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
O. B.
Chief Scientific Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. N.
Chief Technical Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
S. H.
Chief Operating Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

D. B. F.
Chief Regulatory Affairs Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. M.
Chief Business Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
K. C.
Executive Assistant To Chief Scientific Officer
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. T.
Vp, Head Of Technology
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
E. D.
Vice President, Head Of Medical Affairs & Market Access Emea
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Dyne Therapeutics and Millions of Other Companies
Sign up for full access to Dyne Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Dyne Therapeutics

Sarepta Therapeutics

PepGen

Vertex Pharmaceuticals

Beam Therapeutics

ProQR Therapeutics

Rheos Medicines

Generation Bio

Dynacure

Dyno Therapeutics

Prevail Therapeutics

Stoke Therapeutics

Affinia Therapeutics

Dyne Therapeutics Tech Stack

Media & News

Renfund invests into Dyne Tx $4.45M.

Dyne Tx has issues with possible securities related infractions.

Joshua Brumm left Dyne Tx as president and CEO on Mar 1st '24.

Commodorecapital invests into Dyne Tx $12M.

Dyne Tx launches clinical data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD.

Dyne Tx hired John Cox as CEO on Mar 25th '24.

Dyne Tx launched Q4 earnings report on Mar 5th '24.

Dyne Therapeutics's Email Address Formats

Frequently Asked Questions

Where is Dyne Therapeutics's headquarters located?

What is Dyne Therapeutics's phone number?

What is Dyne Therapeutics's stock symbol?

What is Dyne Therapeutics's official website and social media links?

How much revenue does Dyne Therapeutics generate?

What is Dyne Therapeutics's SIC code NAICS code?

How many employees does Dyne Therapeutics have currently?

What industry does Dyne Therapeutics belong to?

What technology does Dyne Therapeutics use?

What is Dyne Therapeutics's email format?

How much funding has Dyne Therapeutics raised to date?

When was Dyne Therapeutics founded?

Dyne Therapeutics

Company Overview

Media & News

Renfund invests into Dyne Tx $4.45M.

Dyne Tx has issues with possible securities related infractions.

Joshua Brumm left Dyne Tx as president and CEO on Mar 1st '24.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?